Forbion is a global venture capital firm based in Naarden, Netherlands, specializing in life sciences, biotech, and bioeconomy investments. Founded in 2006, it has evolved from its origins in the 1990s as ABN AMRO Capital Life Sciences and now manages over €5 billion across various fund strategies. The firm focuses on sourcing, building, and guiding life sciences companies to develop innovative therapies and address health and environmental challenges.
Forbion's investment strategies cover all stages of (bio-)pharmaceutical drug development and include a BioEconomy fund that targets sustainable solutions in food, agriculture, and environmental technologies. The firm collaborates with academic institutions, healthcare companies, and service providers to support early-stage investments and accelerate the growth of its portfolio companies. With a track record of 128 investments across 11 funds, Forbion prioritizes impactful investments that benefit health, well-being, and the planet.